iTeos Therapeutics (Group)

https://www.iteostherapeutics.com

iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic (“cold”) tumors. It has licensed its IDO1 program, currently in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). *

	Start	2012-05-25 splitoff before
	Predecessor	Université Catholique de Louvain (UCLouvain)
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	drug target identification
	Person	Detheux, Michel (iTeos Therapeutics 201205 CEO + Co-founder)
	Person 2	Mertens, Yves (iTeos Therapeutics 201604– CFO before 18y at Aliaxis as CEO + CFO)

	Region	Gosselies
	Country	Belgium
	Street	45 Rue Auguste Piccard Biopark Incubator 2
	City	6041 Gosselies
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2020-06-15)
	Currency	USD
	Annual sales	4,779,000 (grant income + RnD tax credits (2019) 2019-12-31)
	Profit	-22,454,000 (2019-12-31)
	Cash	21,988,000 (2019-12-31)

		* Document for »About Section«: iTeos Therapeutics S.A.. (7/28/17). "Press Release: iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region". Gosselies.

		Record changed: 2024-02-12